Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program

被引：0

作者：

Warren, Richard B. ^{[1
]}

Armstrong, April W. ^{[2
]}

Imafuku, Shinichi ^{[3
]}

Paul, Carle ^{[4
,5
]}

Kircik, Leon ^{[6
]}

Colston, Elizabeth ^{[7
]}

Scharnitz, Thomas ^{[7
]}

Wang, Tao ^{[7
]}

Banerjee, Subhashis ^{[7
]}

Strober, Bruce ^{[8
,9
]}

机构：

[1] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, NIHR Manchester Biomed Res Ctr, Salford, Lancs, England

[2] Univ Southern Calif, Los Angeles, CA USA

[3] Fukuoka Univ Hosp, Fukuoka, Japan

[4] Univ Toulouse, Toulouse, France

[5] CHU, Toulouse, France

[6] Icahn Sch Med Mt Sinai, New York, NY USA

[7] Bristol Myers Squibb, New York, NY USA

[8] Yale Univ, Sch Med, New Haven, CT USA

[9] Cent Connecticut Dermatol Res, Cromwell, CT USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

43879

引用

页码：AB147 / AB147

页数：1

共 50 条

[21] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials
Lebwohl, Mark
Gooderham, Melinda
Warren, Richard B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41
[22] Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Warren, Richard
Armstrong, April W.
Imafuku, Shinichi
Morita, Akimichi
Paul, Carle
Augustin, Matthias
Passeron, Thierry
Kircik, Leon
Vritzali, Eleni
Scharnitz, Thomas
Schroeder, Georgene
Banerjee, Subhashis
Strober, Bruce
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2310 - 2312
[23] Deucravacitinib (DEUC), an Oral, Selective Tyrosine Kinase 2 ( TYK2) Inhibitor, Versus Placebo (PBO) and Apremilast (APR) in Moderate to Severe Plaque Psoriasis: Safety Analysis by Prior Therapy Subgroups in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Eyerich, Kilian
Warren, Richard B.
Blauvelt, Andrew
Gudjonsson, Johann
Sobell, Jeffrey
Banerjee, Subhashis
Balagula, Eugene
Hippeli, Lauren
Gooderham, Melinda
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 120 - 120
[24] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials
Armstrong, April W.
Warren, Richard B.
Sofen, Howard
Spelman, Lynda
Leonardi, Craig
Banerjee, Subhashis
Wang, Tao
Throup, John
Colston, Elizabeth
Napoli, Andrew
Kimball, Alexa B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB156 - AB156
[25] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers
Warren, Richard B.
Lebwohl, Mark
Imafuku, Shinichi
Bagel, Jerry
Armstrong, April W.
Passeron, Thierry
Linaberry, Misti
Hoyt, Kim
Napoli, Andrew
Kisa, Renata M.
Thaci, Diamant
Blauvelt, Andrew
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4346 - 4348
[26] Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials
Lebwohl, Mark
Warren, Richard B.
Kircik, Leon
Colston, Elizabeth
Hippeli, Lauren
Napoli, Andrew
Kisa, Renata M.
Banerjee, Subhashis
Menter, Alan
Thaci, Diamant
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35
[27] Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Lebwohl, Mark
Warren, Richard B.
Sofen, Howard
Imafuku, Shinichi
Paul, Carle
Szepietowski, Jacek C.
Spelman, Lynda
Passeron, Thierry
Vritzali, Eleni
Napoli, Andrew
Kisa, Renata M.
Buck, Alex
Banerjee, Subhashis
Thaci, Diamant
Blauvelt, Andrew
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (05) : 668 - 679
[28] Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
Blauvelt, Andrew
Rich, Phoebe
Sofen, Howard
Strober, Bruce
Merola, Joseph F.
Lebwohl, Mark
Morita, Akimichi
Szepietowski, Jacek C.
Lambert, Jo
Hippeli, Lauren
Colston, Elizabeth
Balagula, Eugene
Banerjee, Subhashis
Thaci, Diamant
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (04) : 775 - 782
[29] Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast: Subset Analysis of Patients With Scalp Psoriasis in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
Thaci, Diamant
Rich, Phoebe
Sofen, Howard
Merola, Joseph
Strober, Bruce
Morita, Akimichi
Szepietowski, Jacek
Colston, Elizabeth
Throup, John
Wang, Tao
Banerjee, Subhashis
Blauvelt, Andrew
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 25 - 25
[30] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial
Imafuku, Shinichi
Okubo, Yukari
Tada, Yayoi
Ohtsuki, Mamitaro
Colston, Elizabeth
Napoli, Andrew
Shao, Yanqiu
Banerjee, Subhashis
Morita, Akimichi
JOURNAL OF DERMATOLOGY, 2024, 51 (03): : 365 - 379

← 1 2 3 4 5 →